Whole exome sequencing is the next-generation technique that is widely preferred as a substitute for whole genome sequencing due to its advantages. As the whole sequencing technique reduces the time and cost of analyzing genetics, it also offers a reduction of time spent in the trial and error for the drug formulation.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005519/
Whole Exome Sequencing Market: Competitive Landscape and Key Developments:
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Centogene AG
- Hoffmann-La Roche AG
- Psomagen, Inc. (previously Macrogen Corp.)
- Pacific Biosciences of California, Inc.
- GENEWIZ, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific
- Stratos Genomics
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876